Transpire Bio
Axel G Perlwitz is currently the Chief Regulatory Affairs Officer at Transpire Bio. With a background in Chemistry, Axel has held various senior positions in regulatory affairs within the pharmaceutical industry, including at Lupin Inhalation Research Center, Glenmark Pharmaceuticals, Teva Branded Pharmaceutical Products R&D Inc., and Cardinal Health / Catalent Pharma Solutions. Axel's experience spans over two decades, with expertise in respiratory drug products and inhalation technologies.
Transpire Bio
We are a team of dedicated professionals with expertise in delivering medicines to the body through the inhaled route. The Leadership Team combined has over 100 years of experience in developing inhaled medicines and bringing these medicines to the U.S. and European markets. Our purpose at Transpire Bio is framed by two core elements: Access and Innovation. For common diseases where adequate therapies exist, we seek to expand access to these complex inhaled medicines globally by developing and commercializing lower-cost generic alternatives. For diseases with few treatment options, we seek to innovate by harnessing existing known mechanisms of action, and dramatically improve the risk-benefit profile of selected molecules by developing these as inhaled therapeutics. Our understanding of the complexities of inhaled drug-device products will allow us to advance these therapies and improve the health of people around the globe.